Roth MKM analyst Boobalan Pachaiyappan raised the firm’s price target on Verona Pharma (VRNA) to $83 from $68 and keeps a Buy rating on the shares after its Q4 earnings beat. The company’s Ohtuvayre demonstrated strong performance despite being a late entrant in the crowded COPD landscape, achieving $36.6M in sales in Q4, with year-to-date prescriptions exceeding Q4 metrics, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma’s Strong Market Position and Growth Potential Drive Buy Rating
- Positive Outlook on Verona Pharma’s Ohtuvayre: Strong Sales, Strategic Positioning, and Growth Potential
- Verona Pharma price target raised to $93 from $74 at Wells Fargo
- Verona Pharma price target raised to $75 from $60 at H.C. Wainwright
- Verona Pharma’s Strong Start with Ohtuvayre Launch